PRRSV recombinant antigen A1 inhibits the expression of CD163 on the cell surface by inducing the polarization of M1 macrophage subset, which can further effectively reduce virus invasionreduce infection. A1 can regulate the endogenous genes of alveolar macrophages to activate Th1-type immune responseenhance cellular immunity. Therefore, this technical invention will be beneficial to screen the new generation of PSSRV candidate structural vaccines.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

"Establish an immunological-based platform for nano drug: 1. Establish macrophages as an in vitro cell-based testing platform 2. Safety assessmentimmunomodulatory effects of nano drugs 3. Gold nanodots as a specific target of Nrf2 pathway against chronic diseases."

Two COVID-19 animal models, including humanized Ace2 micehuman peripheral blood lymphocyte transplanted mice, are used to mimic COVID-19 infection, immune responsecytokine release syndrome in human. The immune analytical platform can further outline the immune cell, cytokinebiomarker response pattern after viral infection. The COVID-19 humanized animal modelthe immune analytical platform will support COVID-19 related researchfacilitate new drugnew therapy validation.

We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.